Study of the effect of food on the bioavailability, safety and tolerability of Aterixen^® 100 mg tablet in healthy volunteers

The aim. The primary objective of the study was to evaluate the effect of food on the bioavailability of Aterixen^® 100 mg tablet after single oral dose under fasting or fed conditions. The secondary objective was to evaluate the pharmacokinetic parameters, safety, and tolerability of Aterixen^® 100 mg tablet after single oral dose under fasting or fed conditions. Materials and methods. Healthy male and female volunteers aged 18 to 45 years were included in the study. Due to lack of data about intra-individual variability of the main pharmacokinetic parameters of the active substance in Aterixen^® (XC221GI, 1-[2-(1-Methylimidazol-4-yl)-ethyl]perhydroazin-2,6-dione), an adaptive group sequential approach was used in the study. At Stage I, 24 volunteers were randomized into 2 groups (12 in each group): Group 1 (sequence AAB) received treatment A (administration of the drug under fasting conditions) during period I, treatment A during period II and treatment B (administration of the drug under fed conditions) during period III, Group 2 (sequence BBA) received therapy B during period I, therapy B during period II, and therapy A during period III. In each study period, serial blood samples were collected before and throughout 12 h after administration of the study drug. The quantification of the active substance XC221GI in plasma samples was performed using a validated high-performance liquid chromatography method with mass spectrometric detection. Safety evaluation was performed on the basis of frequency and severity of adverse events (AEs) and serious adverse events (SAEs), which were registered based on complaints, physical examination, laboratory tests, and electrocardiography (ECG). Drug tolerability was evaluated in terms of proportion of volunteers who prematurely discontinued participation in the study due to AE/SAE. Results. 24 randomized volunteers completed the study in compliance with the approved study protocol. The averaged pharmacokinetic curves profiles of XC221GI had similar shapes under fasting and fed conditions. Confidence intervals for the ratio of the geometric means for the primary parameters (AUC_(0-t) and C_max) of XC221GI and AUC_(0-∞) were within the 80-125 % acceptance interval, while a small in absolute value, but statistically significant differences were noted in time until C_max is reached. Throughout the study, 2 volunteers reported AEs (low RBC count, low hemoglobin concentration, and low hematocrit value) after receiving the study drug under fed conditions. All reported AEs were mild. The relationship between AEs and the study drug product was assessed by investigator as doubtful. Conclusion. The results of this study indicate that food does not affect the bioavailability of Aterixen^® 100 mg, tablets, and the single oral dose of 100 mg was safe and well tolerated by healthy volunteers.

1. Сорокина Е.С., Яхиббаева Д.Р. Статистика коронавируса в РФ за 2020-2021. Международная научно-практическая конференция. 2022;132–137. [Sorokina ES, Yakhibbaeva DR. Statistics of coronaviruses of the Russian Federation for 2020-2021. International scientific conference. 2022;132–137. (In Russ).]

2. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2023. Доступно на https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf

3. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). МЗ РФ. Версия 17 (14.12.2022). [Vremennye metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). MZ RF. Versiya 17 (14.12.2022). (In Russ).].

4. Денисенко А.С., Рисс М.Е., Никитина Н.Н., Кропачев И.Г. Особенности клиники и течения легкой формы коронавирусной инфекции. Вестник НовГУ. Сер.: Медицинские науки. 2022;127(2):94–97. [Denisenko AS, Riss ME, Nikitina NN, Kropachev IG. Features of the clinic and the course of mild coronaviral infection. Vestnik NovSU. Issue: Medical Sciences. 2022;127(2):94–97. (In Russ).]. DOI: 10.34680/2076-8052.2022.2(127).94-97.

5. ИМП. Препарат Атериксен. РУ № ЛП-007921. Дата регистрации 28.02.2022. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=da6eb5f5-e350-446e-80a5-2ab44916fa9b.

6. Отчёт о клиническом исследовании «Многоцентровое, адаптивное, рандомизированное, двойное слепое, плацебо-контролируемое исследование по оценке эффективности и безопасности препарата XC221, таблетки, 100 мг у пациентов с COVID 19 лёгкого течения». Москва: 2022. [Otchet o klinicheskom issledovanii «Mnogocentrovoe, adaptivnoe, randomizirovannoe, dvojnoe slepoe, placebo-kontroliruemoe issledovanie po ocenke effektivnosti i bezopasnosti preparata XC221, tabletki, 100 mg u pacientov s COVID 19 legkogo techeniya». Moscow: 2022. (In Russ).].

7. Отчёт о клиническом исследовании «Открытое рандомизированное перекрестное исследование с 2 видами терапии (натощак и после еды), 3 периодами, 2 последовательностями и адаптивным, двухэтапным дизайном для оценки влияния приема пищи на биодоступность препарата ХС221, таблетки, 100 мг при однократном приеме здоровыми добровольцами». Москва: 2022. [Otchet o klinicheskom issledovanii «Otkrytoe randomizirovannoe perekrestnoe issledovanie s 2 vidami terapii (natoshchak i posle edy), 3 periodami, 2 posledovatel'nostyami i adaptivnym, dvuhetapnym dizajnom dlya ocenki vliyaniya priema pishchi na biodostupnost' preparata HS221, tabletki, 100 mg pri odnokratnom prieme zdorovymi dobrovol'cami». Moscow: 2022. (In Russ).].

8. Molins E, Cobo E, Ocaña J. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose? Stat Med. 2017 Dec 30;36(30):4777–4788. DOI: 10.1002/sim.7452.

9. Potvin D, DiLiberti CE, Hauck WW, et al. Sequential design approaches for bioequivalence studies with crossover designs. Pharm Stat. 2008 Oct-Dec;7(4):245–262. DOI: 10.1002/pst.294.

10. Food-Effect Bioavailability and Fed Bioequivalence Studies. Journal of Korean Pharmaceutical Sciences. 2004 Jun 20;34(3):223–228.

11. Решение Совета Евразийской экономической комиссии № 85 «Об утверждении правил проведения исследований биоэквивалентности лекарственных препаратов в рамках Евразийского экономического союза» от 03.11.2016 г. [Decision of the Council of the Eurasian Economic Commission No. 85 «Ob utverzhdenii pravil provedeniya issledovanij bioekvivalentnosti lekarstvennyh preparatov v ramkah Evrazijskogo ekonomicheskogo soyuza» ot 03.11.2016. (In Russ).].

12. Руководство по экспертизе лекарственных средств ФГБУ «НЦЭСМП» Минздрава России, Том 1, 2013 г. [Rukovodstvo po ekspertize lekarstvennyh sredstv FGBU «NCESMP» Minzdrava Rossii, Vol. 1, 2013. (In Russ).].

13. Koziolek M, Alcaro S, Augustijns P, et al. The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. Eur J Pharm Sci. 2019 Jun 15;134:31–59. DOI: 10.1016/j.ejps.2019.04.003.